Corrie L Poelman1, Laura K Hummers1, Fredrick M Wigley1, Cynthia Anderson1, Francesco Boin1, Ami A Shah2. 1. From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.C.L. Poelman, BA; L.K. Hummers, MD, ScM, Associate Professor of Medicine; F.M. Wigley, MD, Professor of Medicine; C. Anderson, MS; F. Boin, MD, Assistant Professor of Medicine; A.A. Shah, MD, MHS, Assistant Professor of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine. 2. From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.C.L. Poelman, BA; L.K. Hummers, MD, ScM, Associate Professor of Medicine; F.M. Wigley, MD, Professor of Medicine; C. Anderson, MS; F. Boin, MD, Assistant Professor of Medicine; A.A. Shah, MD, MHS, Assistant Professor of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine. ashah32@jhmi.edu.
Abstract
OBJECTIVE: We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc). METHODS: The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test. RESULTS: Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p < 0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (-5.3 ± 7.9) compared to the relaxin trial (-4.8 ± 6.99, p = 0.74) or MMF group (-3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (-8 ± 8.3) than in the D-pen (-2.47 ± 8.6, p = 0.005) and collagen (-3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (-7.1 ± 9, p = 0.67). CONCLUSION: Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.
OBJECTIVE: We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc). METHODS: The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test. RESULTS: Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p < 0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (-5.3 ± 7.9) compared to the relaxin trial (-4.8 ± 6.99, p = 0.74) or MMF group (-3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (-8 ± 8.3) than in the D-pen (-2.47 ± 8.6, p = 0.005) and collagen (-3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (-7.1 ± 9, p = 0.67). CONCLUSION: Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.
Authors: P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold Journal: Arthritis Rheum Date: 2012-10
Authors: Zoltán Szekanecz; Magdolna Aleksza; Péter Antal-Szalmás; Pál Soltész; Katalin Veres; Sándor Szántó; Zoltán Szabó; Anikó Végvári; Szilvia Szamosi; Gabriella Lakos; Sándor Sipka; Gyula Szegedi; John Varga; Gabriella Szücs Journal: Clin Rheumatol Date: 2008-12-06 Impact factor: 2.980
Authors: T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie Journal: J Rheumatol Date: 1999-10 Impact factor: 4.666
Authors: D Khanna; D E Furst; R D Hays; G S Park; W K Wong; J R Seibold; M D Mayes; B White; F F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V D Steen; R W Martin; D Collier; A Weinstein; E V Lally; J Varga; S R Weiner; B Andrews; M Abeles; P J Clements Journal: Ann Rheum Dis Date: 2006-03-15 Impact factor: 19.103
Authors: Sogol Amjadi; Paul Maranian; Daniel E Furst; Philip J Clements; Weng Kee Wong; Arnold E Postlethwaite; Puja P Khanna; Dinesh Khanna Journal: Arthritis Rheum Date: 2009-08
Authors: F Nacci; A Righi; M L Conforti; I Miniati; G Fiori; D Martinovic; D Melchiorre; T Sapir; M Blank; Y Shoenfeld; A Moggi Pignone; M Matucci Cerinic Journal: Ann Rheum Dis Date: 2007-03-07 Impact factor: 19.103